Last reviewed · How we verify
NCT06046274
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
Phase 2 trial testing Pembrolizumab in Advanced Endometrial Cancer. Withdrawn.
1 April 2028
Quick facts
| Lead sponsor | Genmab |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 October 2023 |
| Primary completion | 1 April 2028 |
| Estimated completion | 1 June 2028 |
| Sites | 29 locations across Denmark, Italy, Belgium, South Korea, United States, Spain |
Drugs / interventions tested
- Pembrolizumab (pembrolizumab) — full drug profile →
- Acasunlimab — full drug profile →
Conditions studied
- Advanced Endometrial Cancer — all drugs for Advanced Endometrial Cancer →
Sponsor
Genmab — full company profile →
Who can join
18 and older, female only, with Advanced Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical study is to learn about the bispecific antibody, acasunlimab (also known as GEN1046) in combination with the cancer drug pembrolizumab for treatment of participants with incurable endometrial cancer (cancer of the womb). The main questions the study aims to answer are: * How well acasunlimab in combination with pembrolizumab works against endometrial cancer * What are the potential side effects participants may experience when they are treated with acasunlimab in combination with pembrolizumab Participants will receive both acasunlimab and pembrolizumab. All participants will receive active drug; no one will receive placebo. participants will participate in 1 of 2 cohorts. A participant will receive study treatment up to a maximum of 24 months. The study duration (including screening, treatment, and follow-up) for each participant will be about 39 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06046274
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
Other recruiting trials for Advanced Endometrial Cancer
Currently open trials in the same condition.
- NCT06584032 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer · Phase 3 · recruiting
- NCT06758557 — A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor · Phase 1, PHASE2 · recruiting
Other Genmab trials
Trials by the same sponsor.
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07288177 — Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT06984328 — Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin · Phase 2 · active not recruiting
- NCT06771921 — A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06046274 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genmab
- Last refreshed: 30 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06046274.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing